Peptide Research Glossary

The fundamental building blocks of peptides and proteins. There are 20 standard amino acids, each with a central carbon atom bonded to a hydrogen, an amino group (−NH₂), a carboxyl group (−COOH), and a unique side chain (R-group) that determines the amino acid's chemical properties. The sequence of amino acids in a peptide chain determines its three-dimensional structure and function.

The physiological process of new blood vessel formation from pre-existing vessels. Several research peptides (most notably BPC-157 and GHK-Cu) have been shown to upregulate angiogenic growth factors including VEGF (Vascular Endothelial Growth Factor) and FGF-2, stimulating new capillary formation. This mechanism is thought to underlie many of the tissue-healing effects observed in peptide research.

A form of cell signaling in which a cell secretes a substance (ligand) that binds to receptors on the same cell, producing a self-regulatory effect. Some peptides act via autocrine mechanisms — the peptide produced by a cell acts back on that same cell. Contrast with paracrine (acts on neighboring cells) and endocrine (acts distally via bloodstream) signaling.

Sterile water for injection containing 0.9% benzyl alcohol as a preservative. Benzyl alcohol inhibits bacterial growth without killing cells, making it suitable for multi-dose vials. Bacteriostatic water is the standard diluent for reconstituting research peptides for storage — it extends solution stability to 4–6 weeks at 4°C. Not to be confused with sterile water for injection (no preservative) or normal saline (0.9% sodium chloride).

A key neurotrophin that supports the survival, growth, and maintenance of neurons. BDNF plays a critical role in synaptic plasticity, long-term potentiation (LTP), and neurogenesis. Several research peptides — particularly Semax and Dihexa — have been shown to upregulate BDNF or potentiate its downstream signaling via the TrkB receptor pathway, which may explain their observed nootropic effects.

The fraction of an administered dose of a compound that reaches systemic circulation in its active form. Oral bioavailability of most peptides is extremely low (<5%) due to proteolytic degradation in the GI tract and poor permeability across intestinal epithelium. This is why most research peptides are administered via subcutaneous or intramuscular injection, which achieves bioavailability of 80–95% for most lyophilized peptides.

The two ends of a peptide chain. The N-terminal (amino terminal) is the end with a free amino group (−NH₂); the C-terminal (carboxyl terminal) has a free carboxyl group (−COOH). By convention, peptide sequences are written from N-terminal (left) to C-terminal (right). Many peptide modifications involve protecting one or both termini to increase stability — for example, C-terminal amidation protects against exopeptidase cleavage and is used in several research peptides.

A document issued by a laboratory certifying the results of quality control testing for a specific batch of compound. A research-grade COA should include: HPLC purity percentage, mass spectrometry confirmation of molecular weight, lot/batch number, testing date, and testing laboratory identification. Third-party COAs (issued by an independent lab) are substantially more reliable than in-house COAs (issued by the vendor's own laboratory).

A proprietary modification in which a peptide is conjugated to a reactive group that covalently binds to serum albumin after injection. Albumin has a long serum half-life (~19 days), so albumin-bound peptides persist much longer in circulation. CJC-1295 DAC uses this technology to extend the half-life of the GHRH analog from ~30 minutes to 6–8 days, enabling weekly dosing protocols.

Peptides consisting of exactly two (dipeptide) or three (tripeptide) amino acids linked by peptide bonds. Despite their small size, dipeptides and tripeptides can have significant biological activity — for example, GHK (Glycine-Histidine-Lysine) is a tripeptide with documented copper-chelating, wound-healing, and gene-regulatory properties. Some tripeptides have better oral absorption than longer peptides.

The relationship between the dose of a compound and the magnitude of its biological effect. Research peptides typically show a sigmoidal dose-response curve: low doses produce minimal effect, medium doses produce proportional effects, and high doses plateau (ceiling effect). Some peptides show a biphasic (bell-shaped) dose-response where very high doses produce diminishing or reversed effects — an important consideration in research protocol design.

The half-maximal effective concentration — the concentration of a compound that produces 50% of its maximum possible effect. EC50 is a key measure of a compound's potency: a lower EC50 indicates a more potent compound. Related: IC50 (inhibitory concentration 50%) is used for compounds that inhibit a response. Both values are derived from dose-response curves and are essential reference points in receptor binding studies.

Produced or originating within the organism. Endogenous peptides are naturally produced by the body and serve physiological functions. Many research peptides are either identical to endogenous peptides (e.g., Thymosin α1, which is naturally produced by the thymus) or are synthetic analogs designed to mimic or enhance endogenous peptide function. The endogenous nature of a peptide's target provides a rationale for why it may have physiological effects.

The study of heritable changes in gene expression that do not involve changes to the underlying DNA sequence. Epigenetic mechanisms include DNA methylation, histone modification, and non-coding RNA regulation. Epithalon (Epitalon) is of particular research interest for its proposed epigenetic effects, specifically its ability to activate telomerase and modulate the expression of genes involved in aging and circadian rhythm regulation.

A protease (protein-cleaving enzyme) that cleaves amino acids from the termini (ends) of a peptide chain, rather than from the middle. Exopeptidases are a major cause of peptide degradation in plasma and tissues. C-terminal amidation and N-terminal acetylation are common peptide modifications specifically designed to protect against exopeptidase cleavage, extending a peptide's effective half-life.

An endogenous hypothalamic peptide that stimulates the pituitary gland to synthesize and secrete growth hormone (GH). GHRH acts via the GHRH receptor (GHRHR) on somatotroph cells. Several research peptides (CJC-1295, Sermorelin, Tesamorelin) are synthetic GHRH analogs that mimic this action with enhanced stability. These are often combined with GHSR agonists (GHRPs) to produce synergistic GH release.

A class of synthetic peptides that stimulate growth hormone secretion by acting on the ghrelin receptor (GHSR-1a) in the pituitary and hypothalamus. Unlike GHRH analogs (which stimulate GH via the GHRH receptor), GHRPs work through a different receptor, making them synergistic when combined. Major GHRPs include Ipamorelin, GHRP-6, GHRP-2, and Hexarelin, each with differing selectivity and potency profiles.

The receptor for ghrelin — a hunger-signaling peptide — located in the pituitary, hypothalamus, and peripheral tissues. GHRPs work by acting as GHSR agonists. The GHSR has two subtypes: GHSR-1a (functional receptor that mediates GH release) and GHSR-1b (truncated form without full signaling capacity). Ipamorelin is notable for its high selectivity for GHSR-1a with minimal effects on other receptors.

An incretin hormone produced by L-cells in the small intestine in response to food intake. GLP-1 stimulates insulin secretion, inhibits glucagon release, delays gastric emptying, and reduces appetite via central receptors. Semaglutide, Tirzepatide, and Retatrutide are GLP-1 receptor agonists that mimic and extend GLP-1 action, forming the basis of the most effective weight-loss and type 2 diabetes research compounds currently known.

The largest receptor superfamily in the human genome, comprising over 800 different receptors. GPCRs are transmembrane proteins that, when activated by a ligand, couple to intracellular G-proteins to trigger downstream signaling cascades. Many research peptide targets are GPCRs, including the GHSR (ghrelin receptor), GLP-1R (GLP-1 receptor), and melanocortin receptors. GPCR-targeting peptides often have favorable selectivity profiles.

A secreted protein or polypeptide that binds to specific receptors on target cells to promote cell growth, proliferation, differentiation, or survival. Key growth factors relevant to peptide research include: IGF-1 (Insulin-like Growth Factor 1), VEGF (Vascular Endothelial Growth Factor), EGF (Epidermal Growth Factor), and TGF-β (Transforming Growth Factor beta). Several research peptides work by upregulating or modulating growth factor expression.

The time required for the plasma concentration of a compound to decrease by 50% from its peak level. After 5 half-lives, approximately 97% of the compound has been eliminated. Half-life is a primary determinant of dosing frequency: compounds with short half-lives (GHRP-6: ~30 min) require multiple daily dosing, while those with long half-lives (CJC-1295 DAC: ~6–8 days; Semaglutide: ~7 days) require only weekly dosing.

An analytical technique used to separate, identify, and quantify components in a mixture. In peptide quality control, HPLC is the primary method for measuring purity — it separates the target peptide from impurities (truncated sequences, oxidized variants, degradation products) based on differences in interaction with the stationary phase. The purity is calculated as the area under the target peak divided by total peak area × 100. Research-grade peptides should have ≥97–99% HPLC purity.

A peptide hormone with high structural similarity to insulin, produced primarily in the liver in response to GH stimulation. IGF-1 mediates many of GH's anabolic effects — it promotes protein synthesis, muscle growth, bone growth, and cell survival. The research compound IGF-1 LR3 is a synthetic long-acting analog with a 13-amino acid extension that reduces IGF-binding protein affinity, extending its effective half-life from ~15 minutes to ~20–30 hours.

A class of gastrointestinal hormones that stimulate insulin secretion in response to food intake. The two main incretins are GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-dependent Insulinotropic Polypeptide). GLP-1 receptor agonists like Semaglutide mimic the action of GLP-1 with extended half-life. Tirzepatide is a dual GLP-1/GIP agonist; Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors.

A measure of the binding affinity of a compound for a receptor or enzyme in an inhibition context — specifically, the concentration at which a competitive inhibitor occupies 50% of its target sites when competing with the natural ligand. A lower Ki indicates higher binding affinity. Ki differs from EC50 in that Ki is a thermodynamic constant describing affinity, while EC50 describes functional potency (effect magnitude).

Any molecule that binds to a specific receptor to produce a biological effect. In the context of research peptides, the peptide is typically the ligand and the receptor is the macromolecular target. Ligands can be agonists (activate the receptor), antagonists (block the receptor without activating it), or partial agonists (partially activate the receptor). The affinity and efficacy of peptide-receptor binding are the primary determinants of pharmacological activity.

Freeze-drying — the process of removing water from a frozen peptide solution under vacuum conditions. The ice sublimes directly from solid to vapor without passing through a liquid phase. The result is a stable, porous powder (lyophilizate) that can be stored for years at -20°C or months at 4°C. Lyophilization is the industry standard for research peptide preservation because it dramatically extends shelf life without damaging molecular structure.

An analytical technique that measures the mass-to-charge ratio (m/z) of molecules. For peptide quality control, mass spectrometry confirms molecular identity — it verifies the measured molecular weight matches the theoretical molecular weight of the target peptide, confirming that the correct sequence was synthesized. Combined with HPLC (LC-MS), it is the most definitive identity confirmation available for research peptides.

The specific biochemical process by which a compound produces its pharmacological effect. For peptide research, understanding MOA is essential for predicting interactions, selecting stacking partners, and interpreting research outcomes. For example, BPC-157's MOA includes: upregulation of VEGF and FGF-2 (angiogenesis), activation of the FAK-paxillin pathway (wound healing), and nitric oxide modulation (gastric protection).

The sum of atomic masses of all atoms in a molecule, measured in Daltons (Da) or unified atomic mass units (u). Molecular weight is a primary identifier for peptides — it is used to confirm identity via mass spectrometry and to calculate molar quantities for dosing. As a rough reference: each amino acid adds approximately 110–130 Da to a peptide's molecular weight. BPC-157 (15 amino acids): 1419.53 Da; Semaglutide (31 amino acids): 4113.58 Da.

The brain's ability to reorganize itself by forming new neural connections throughout life. Neuroplasticity encompasses synaptic strengthening, axonal sprouting, neurogenesis (new neuron formation), and cortical remapping. Peptides like Semax, Dihexa, and Cerebrolysin are of research interest for their potential to enhance neuroplasticity — primarily through upregulation of BDNF, NGF, and other neurotrophins that support synaptic plasticity.

A peptide consisting of a small, defined number of amino acids — typically 2–20 residues. The prefix 'oligo-' derives from Greek for 'few.' Many research peptides are oligopeptides: BPC-157 has 15 residues, TB-500 has 43 residues (though the functional fragment Tβ4 is shorter), and GHK-Cu is a tripeptide (3 residues). Oligopeptides have molecular weights generally below ~2500 Da and may have improved tissue penetration compared to larger proteins.

A molecule consisting of a short chain of amino acids linked by peptide bonds. By convention, chains of 2–50 amino acids are called peptides; longer chains are proteins. Peptides occupy a unique pharmacological niche — smaller and more accessible than proteins (which cannot easily cross cell membranes) but more specific and structured than small molecule drugs. Research peptides are typically synthetic and administered to bind specific biological receptors or enzymes.

The covalent chemical bond formed between the carboxyl group (−COOH) of one amino acid and the amino group (−NH₂) of the next, with the loss of a water molecule (condensation reaction). Peptide bonds are the primary structural linkages in all peptide and protein chains. The peptide bond has partial double-bond character, which restricts rotation and contributes to the planar structure of the peptide backbone. Most peptide degradation in biological systems occurs via hydrolysis of peptide bonds by proteases.

The study of what a drug or research compound does to the body — the mechanisms of action, receptor interactions, dose-response relationships, and biological effects. While pharmacokinetics (PK) describes exposure, pharmacodynamics (PD) describes effect. The PK-PD relationship is used to model how changing dose or dosing frequency affects the magnitude and duration of biological effect.

The study of what the body does to a drug or research compound over time — encompassing Absorption, Distribution, Metabolism, and Elimination (ADME). Key PK parameters for research peptides include: half-life (t½), volume of distribution (Vd), clearance (CL), and bioavailability (F). Understanding a peptide's PK profile is essential for designing appropriate dosing intervals and predicting systemic exposure.

An enzyme that catalyzes the hydrolysis of peptide bonds, breaking down peptide and protein chains into smaller fragments. The human body contains hundreds of proteases in plasma, tissues, and the GI tract. Proteolytic degradation by plasma proteases is the primary reason most peptides have short half-lives (minutes to hours) and poor oral bioavailability. Many peptide modifications (D-amino acid substitution, cyclization, PEGylation) are designed specifically to resist protease cleavage.

An agonist is a ligand that binds to a receptor and activates it, producing a biological response. A full agonist produces the maximum possible response; a partial agonist produces a submaximal response even at full receptor occupancy. An antagonist binds to the receptor without activating it, blocking agonist access. Most research peptides are receptor agonists — they mimic endogenous signaling molecules. Understanding agonist/antagonist classification is fundamental for interpreting peptide research literature.

The process of dissolving a lyophilized (freeze-dried) peptide powder in a liquid diluent to create a solution for research use. The standard diluent for most research peptides is bacteriostatic water (BW). Reconstitution must be performed with precise technique: inject the diluent slowly down the vial wall, swirl gently (do not shake), allow the powder to dissolve completely, and verify the solution is clear before use.

The process by which a cell converts an extracellular signal (such as a peptide binding to its receptor) into an intracellular response. The sequence is: signal → receptor activation → second messenger generation → kinase cascade → transcription factor activation → gene expression change → biological effect. Peptides produce their effects through signal transduction — understanding which pathways are activated helps predict downstream effects and potential interactions with other research compounds.

Injection into the subcutaneous tissue — the layer of fat and connective tissue beneath the skin but above the muscle. Subcutaneous injection is the most common administration route for research peptides in preclinical studies. It provides slower, more sustained absorption compared to intravenous injection, making it more suitable for peptides requiring steady plasma levels. Typical SQ injection sites in animal research include the scruff (nape) of the neck.

Telomeres are repetitive DNA sequences (TTAGGG in humans) that cap the ends of chromosomes, protecting them from degradation and fusion. They shorten with each cell division — a key mechanism of cellular aging. Telomerase is the enzyme that synthesizes new telomere repeats, counteracting this shortening. Epithalon (Epitalon) is of research interest specifically for its purported ability to activate telomerase expression, potentially extending cellular replicative lifespan.

A family of peptides originally isolated from thymic tissue, involved in immune system development and regulation. The two most researched thymosins are: Thymosin α1 (Tα1), which stimulates T-cell maturation and immune function, and Thymosin β4 (Tβ4), which promotes tissue repair, anti-inflammation, and angiogenesis. TB-500 is a synthetic peptide derived from the active fragment of Thymosin β4 (residues 17–23: Ac-LKKTETQ).

A family of signaling proteins that stimulate angiogenesis (new blood vessel formation). VEGF-A is the primary pro-angiogenic factor; it binds to VEGFR1 and VEGFR2 receptors on endothelial cells, stimulating their proliferation and migration to form new vessels. BPC-157 and GHK-Cu are of research interest partly because they have been shown to upregulate VEGF expression in preclinical wound healing studies.

A pharmacokinetic parameter that describes the apparent volume a drug would need to occupy if its concentration were uniform throughout the body at the same concentration as in plasma. A high Vd indicates the compound distributes extensively into tissues; a low Vd suggests it remains primarily in plasma. For peptides, Vd is typically low to moderate — many peptides have limited tissue penetration due to their size and hydrophilicity.